 Immunotherapy, Adoptive
"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 0 | 2 | | 1998 | 1 | 0 | 1 | | 2001 | 1 | 1 | 2 | | 2002 | 2 | 2 | 4 | | 2003 | 2 | 0 | 2 | | 2004 | 1 | 1 | 2 | | 2005 | 0 | 1 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 2 | 1 | 3 | | 2009 | 1 | 1 | 2 | | 2010 | 2 | 1 | 3 | | 2011 | 1 | 0 | 1 | | 2012 | 3 | 3 | 6 | | 2013 | 4 | 1 | 5 | | 2014 | 8 | 4 | 12 | | 2015 | 6 | 4 | 10 | | 2016 | 10 | 3 | 13 | | 2017 | 7 | 3 | 10 | | 2018 | 12 | 4 | 16 | | 2019 | 19 | 4 | 23 | | 2020 | 15 | 4 | 19 | | 2021 | 18 | 13 | 31 | | 2022 | 5 | 17 | 22 | | 2023 | 4 | 26 | 30 | | 2024 | 15 | 9 | 24 | | 2025 | 39 | 1 | 40 | | 2026 | 15 | 6 | 21 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Lin HK, Blake DA, Freeman R, Chen Y, Kim J, Johnson AM, Wells K, Mudigonda A, Liu W, Yadav P, Zeng F, Muhuri A, Min K, Sarkar S, Wang Y, Goyal S, Roberts RC, Christensen E, Ward AB, Heller B, Chun P, Dougan J, Porter CC, Barwick BG, Paulos CM, Yang L, Patgiri A, Thomas SN, Waller EK, Rafiq S. Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models. Sci Transl Med. 2026 Jul 22; 18(859):eadt9565.
-
de Jong D, McGale JP, Robinson TJ, Liao MJ, Das JP, Major A, Capaccione KM, Ladbury C, Mansilla-Soto J, Ma H, Al Feghali KA, Goy AH, Lopci E, Reshef R, Schwartz LH, Houot R, Dercle L. CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment. J Nucl Med. 2026 Jul 01; 67(7):1021-1031.
-
Kamdar M, Bartlett NL. From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma. Blood. 2026 Jun 11; 147(24):2879-2894.
-
Sharp J, Strati P, Bhatta S, Huang JJ, Thomas C, Elghawy O, Reef D, Gorzewski A, Wang J, Shouse G, Reinert C, Teferra A, Velez ET, Pelcovits A, Ollila T, Clark W, Yazbeck V, Maakaron J, Kamdar M, Fitzgerald L, Danilov A, Karmali R, Grover NS, Barta SK, Voorhees TJ, Chen AI, Shadman M, Ahmed S, Epperla N. Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study. Blood Adv. 2026 Jun 09; 10(11):3757-3768.
-
Silbert SK, Gava F, Yates B, Rankin AW, Rocco JM, Shao L, Dreyzin A, Cai Y, Lamplugh C, Han KL, Prochazkova M, Little L, Foley T, Sankaran H, Martin K, Garces P, Jin P, Chien CD, Taylor N, Fry TJ, Yuan CM, Wang HW, Stroncek DF, Highfill SL, Shalabi H, Shah NN. CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results. J Immunother Cancer. 2026 Jun 05; 14(6).
-
Magno JC, Guo J, Hall SC, Liu J, Albert GK, Carter JD, Davalos AS, Cao P, Bangar A, Drigot Z, Hudson H, Geluck T, Nevala WK, Markovic SN, Wilky BA, Davila E. Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses. Cancer Res. 2026 Jun 01; 86(11):2688-2702.
-
Xiao Y, Bai M, Ang MJY, Mitchell MJ, Han X. Transient T cell therapies. Adv Pharmacol. 2026; 106:179-212.
-
Bermack C, Singh S, Pei G, Patel SP, Wang L, Yee C. First-in-human use of recombinant IL-7 to potentiate antigen-specific T cell therapy: a single patient case study. J Immunother Cancer. 2026 Apr 30; 14(4).
-
Gattinoni L, Inchingolo G, Harrer DC, Susana A, Puccio S, Slavkovic-Lukic D, Natrakul DA, Strieder N, Heuser-Loy C, Baldwin JG, Fioravanti J, Ji Y, Gautam S, Suriano C, MartÃn-Santos A, Schelker RC, Patel N, Mann J, Goff S, Mikkilineni L, Yang JC, Kwong MLM, Patel R, Rehli M, Highfill SL, Stroncek DF, Rosenberg SA, Biasco L, Lugli E, Brudno JN, Kochenderfer JN. Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse. Cell. 2026 Jun 11; 189(12):3686-3700.e10.
-
Kim D, Moon SJ, Han EL, Feng E, Murray AM, Wang J, Liu W, Kong G, June CH, Mitchell MJ. HITE: HIV Inspired Lipid Nanoparticle Platform for CAR T Cell Engineering. Nano Lett. 2026 May 06; 26(17):5668-5679.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|